Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.46400Source: DataRank Database

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma is a research paper published in JAMA Network Open (2022). On theSindex it has a DataRank of 0. It has been cited 33 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access33 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.51)OA: goldTopics (41)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Kasey L. Couts ORCID,Erin E. Baschal ORCID,Kagan E. Karakus ORCID,Robert J. Van Gulick ORCID,Jacqueline A. Turner ORCID

Live enrichment

PubMed:36512357 PMC:PMC9856415 OpenAlex:https://openalex.org/W4311311569

NIDDK NIH HHS

Grant: R01 DK032083

NIDDK NIH HHS

Grant: R01 DK108868

NIDDK NIH HHS

Grant: P30 DK116073

FWCI

2.51

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2799441/akturk_2022_oi_221310_1670339201.56871.pdf

publisherhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2799441/akturk_2022_oi_221310_1670339201.56871.pdf

journalhttps://doi.org/10.1001/jamanetworkopen.2022.46400

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36512357

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9856415

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchFemaleHumansMaleMiddle AgedAllelesAntineoplastic Agents, ImmunologicalCase-Control StudiesHLA-DR AntigensImmune Checkpoint InhibitorsMelanomaCutaneous Malignant Melanoma

MeSH Terms

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsMelanoma, Cutaneous MalignantCutaneous Malignant MelanomaAllelesFemaleHLA-DR AntigensHumansMaleMelanomaMiddle AgedCase-Control Studies

Keywords

MedicineMelanomaAdverse effectHuman leukocyte antigenInternal medicineImmune systemOncologyImmunotherapyImmune checkpointCancerSurvival analysisAntigenCohortImmunologyCancer research

Sustainable Development Goals

SDG 0: Good health and well-being